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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common kidney genetic disease with a prevalence from 1:400 to 1:1000 live births, characterised by multiple and bilateral cystic dilatation of the renal tubules that lead to an enlargement in the total kidney volume (TKV) and to kidney failure. ADPKD can arise from mutations in either the PKD1 gene (cr. 16p13.3), which encodes the protein polycystin 1 or the PKD2 gene (cr. 4p13q23), encoding polycystin 2.
1 PKD1-associated disease presents a more severe prognosis and an earlier progression to end-stage renal disease (ESRD) in respect to PKD2, with the mean age of 54 years for PKD1 and 74 years for PKD2 developing renal failure. 2 The renal function remains normal for many years with an unpreventable rapid decline in the final stage of disease in ADPKD patients. Caroli et al. 3 showed that in an advanced stage of disease, the main component of the damage is tubulointerstitial fibrosis. Fibroblasts and collagen fibres build up in the parenchyma with different distribution: collagen Types I and III are located in the interstice, while collagen Type IV is in the basement membrane. Interstitial fibrosis could come from cortical ischaemia produced by the vascular lesions and luminal narrowing. 4, 5 The tubulointerstitial damage could also be caused by cytokines and chemokines released from inflammatory cells present in kidney tissue; this is also supported by large infiltrates of macrophages in the fibrotic tissue. Another important role in the proinflammatory factors secretion could be played by aldosterone. High levels of aldosterone enhance the expression of osteopontin, MCP-1, IL-6 and IL-1β. Aldosterone has also direct proliferative and fibrogenetic activity, respectively mediated by its functions on mitogen-activated protein kinase in the nucleus and its ability to increase TGFβ production. 6, 7 All these mechanisms are very important because currently we have need of novel biomarkers of functional loss and indexes of disease progression, especially for testing new therapeutic strategies. The evaluation of fibrotic progression in ADPKD kidneys, estimated with specific magnetic resonance imaging (MRI) sequences, could be a promising predictive factor for the evaluation of the onset of renal damage. 8 This study aimed to identify and quantify the parenchymal fibrotic tissue as a possible marker of kidney damage at an early stage of the disease with MRI, correlating with the estimated glomerular filtration rate (eGFR), predicting the loss of kidney function.
Methods
The study protocol was approved by the Local Clinical Research Ethics Committee with protocol number 3169/15. The study conforms to the principles outlined in the Declaration of Helsinki and we obtained a written consent from each patient enrolled.
Study design and subjects
We performed a prospective longitudinal study on ADPKD patients at the University Hospital 'Policlinico Umberto I' of Rome, Sapienza University of Rome, Italy. Patients were consecutively enrolled from July 2010 to June 2016. Clinical, laboratory, instrumental parameters were evaluated at baseline (T0) and at 5 years (T1).
Patients
A total of 15 ADPKD patients (4 males and 11 females, mean age 39.0 AE 9.2 years) was evaluated at the time of diagnosis (T0) and after follow up (T1). The eGFR was evaluated according to the modification of diet in renal disease formula, 9 chronic kidney disease epidemiology (CKD-EPI) and creatinine clearance in 24-h urine. We enrolled both normotensive and hypertensive patients. The state of arterial hypertension was defined by use of hypotensive drugs (angiotensin converting enzyme (ACEI), angiotensin II receptor blockers (ARB), betablockers, calcium antagonists, alpha-lytic and/or diuretics) or by the presence of a pressure higher than 140/80 mmHg in three consecutive measurements.
Patients on antihypertensive treatment with ACEI and/or ARB, beta-blockers and alpha-lytic have been subjected to a wash-out period of 15 days by replacing the hypotensive therapy with clonidine.
Inclusion criteria
We included patients aged >18 years with diagnosis of ADPKD, defined according to Pei's criteria. 10 
Exclusion criteria
We excluded patients having kidney surgery, or submitted to cyst drainage procedures, or patients with other diseases that can potentially affect kidney function, patients with metal clip carriers and pregnant or nursing patients. Patients that refused to give consent and patients with missing data were also excluded.
Laboratory measurements
Blood was drawn in the morning after overnight fasting of at least 12 h. In all patients, the levels of fasting plasma glucose (mg/dL), insulin (μU/mL), total serum cholesterol (mg/dL), triglycerides (mg/dL), high-density lipoprotein (mg/dL), creatinine (mg/dL), serum nitrogen (mg/dL), serum uric acid (mg/dL), calcium (mg/dL), phosphorus (mg/dL), serum electrolytes (mEq/L), Creactive protein (μg/L), homocysteine (μmol/L) were measured using standard automated techniques. Lowdensity lipoprotein-cholesterol was calculated using the Friedewald equation: low-density lipoprotein (mg/dL) = total cholesterol − high-density lipoprotein − (triglycerides/5). Parathyroid hormone was measured using a two-site assay that measures 'intact' hormone (iPTH) (pg/mL) and 25-hydroxyvitamin D (25-OH-VitD) (ng/mL) was measured by radioimmunoassay. Serum albumin (g/dL) was determined by the bromcresol purple method. Insulin resistance was assessed using the homeostasis model assessment originally described by Mathew et al.
11 Microalbuminuria 24 h (30-300 mg/24 h) was carried out. The determination of plasma renin activity (PRA) was performed by radioimmunoassay tests using a commercial kit (Ren CTK, Sorin Biomedica, Saluggia, Italy). The normal range at rest and with normal sodium diet was 0.2-2.7 ng/mL/h. The determination of plasma aldosterone concentration (PAC) was performed by RIA tests using a commercial kit (Aldosterone Maia Kit, Adaltis Italia S.p.A., Bologna, Italy).
Blood pressure measurements
Clinic blood pressure (BP) measurements were made three times after 10 min of rest in a seated position, using a standard automatic sphygmomanometer and cuffs adapted to the arm circumference, according to the British Hypertension Society guidelines. 13 The mean values for systolic blood pressure (SBP) and diastolic BP (DBP) were then calculated for all participants. The SBP and DBP levels were taken as the points of appearance and disappearance of Korotkoff sounds respectively. Hypertension was defined as SBP ≤ 140 mmHg or DBP ≤ 80 mmHg on repeated measurements. We determined ankle/brachial index (ABI), the measurement of the ratio of the systolic blood pressures in the ankle and in the arm (normal values 0.9-1). 14 
Echocardiography
All patients underwent transthoracic echocardiography with a commercially available cardiovascular ultrasound system (Vivid E9, GE, Horten, Norway). Measurements of cardiac chambers were made according to established criteria. 15 Left ventricular ejection fraction, by modified biplane Simpson method, and left ventricular mass index (LVMI) were estimated. Peak early (E) and late (A) diastolic velocities, deceleration time, left ventricular isovolumic relaxation time, and myocardial performance index were obtained using standard Doppler practices. Standard parasternal, apical and subcostal views were used. 16 
Common carotid intima-media thickness assessment (IMT)
Right and left carotid ultrasound was blindly performed by an experienced sonographer (SL) who was unaware of the characteristics of the patients under examination. Participants were studied with the high-resolution B-mode ultrasound machine, Toshiba Aplio XV (Toshiba Aplio XV, Toshiba American Medical Systems, Inc., Tustin, CA, USA) equipped with a 5-to 12-MHz linear transducer with a 0.01-mm resolution, following a standardised vascular protocol. IMT was measured at three points on the far walls of both left and right distal common carotid arteries, carotid bulb, and the proximal portion of the internal carotid arteries. 17 The mean IMT was computed as the average IMT on both sides. The value of IMT was considered normal when between 0.55 and 0.9 mm. 18 
Magnetic resonance imaging
All patients were subjected to a novel MRI protocol of advanced imaging with magnet 3T (Discovery MR 750, 3T, GE Healthcare) after positioning of the surface coil 32 channels. Thickness 200 mm; FoV 300 × 300 mm, matrix 192 × 138) during administration dynamic of i.v. contrast (gadobutrol 1 mmoL/mL, Gadovist, Bayern, Germany) using a perfusion technique, with high temporal resolution of 4 s, for a total duration of about 8 min. The end of the dynamic sequence was made to coincide with the start of the administration of contrast material i.v. 19 The evaluation of total perfusion volume (TPV) and total fibrotic volume (TFV) results from perfusional MRI after a qualitative and quantitative approach. Each parameter resulted from a post-processed slice by slice renal segmentation respectively in early arterial phase (first minute of perfusion) and late perfusional phase (eighth minute of perfusion). Segmentation was guided using colorimetric maps. After segmentation, software Workstation vers. 4.6 was used for three-dimensional (3D) volume rendering reconstruction, which resulted in semiquantitative estimation of parenchymal perfonded tissue and fibrotic areas. These perfusional parameters give indication of functional parenchymal areas. Perfusion volume indicates kidney areas where blood flow is preserved, which is an indirect sign of normal functional parenchyma. Fibrotic areas indicate parenchymal areas that underwent fibrotical substitution and consequent loss of function.
Image analysis

Morphological assessment
In the morphological images HASTE T2 and T1-weighted 3D GRE, the following parameters were evaluated: kidney size on three floors of acquisition (axial sagittal and coronal), cortical thickness, cortico-medullary differentiation, volume of cysts. In the 3D T1 weighted GRE sequences, the morphological characteristics and the signal intensity, relating to the presence or absence of high protein content, have been evaluated, allowing the identification of haemorrhagic cyst content, infected cysts and degenerate cysts.
Qualitative and quantitative assessment
The perfusion technique was evaluated with both a qualitative and quantitative approach. In the first case, two types of colorimetric maps were obtained, both reconstructed at an early stage than at a late stage. The colorimetric map elaborated in the early stage reflects an enhancement of arterial type, derived from the analysis of the early stages, which identify the normally perfused renal parenchyma, and which may be defined as 'functional'. The colorimetric map developed in the late phase, shows the strengthening of focal renal parenchymal areas that may identify areas of parenchymal fibrosis. The colorimetric maps also allow a 3D reconstruction of the kidney (volume rendering achieved by GE, Workstation software version 4.6) to highlight the renal parenchyma perfused, called 'perfusion volume'. This result was obtained by using the colorimetric map derived from early-stage acquisitions that correspond to approximately 35 s after the beginning of injection of the contrast medium and the colorimetric maps obtained in the late phase, which corresponds to about 8 min from the start of injection of the contrast agent; the latter made it possible to evaluate the estimate of parenchymal fibrosis defined as 'fibrotic volume'. 20 
Statistical analysis
Data management and analysis were performed using IBM SPSS Statistics 22.0 for Windows software (IBM Corporation, Armonk, NY, USA). The normality of variables was tested using the Shapiro-Wilk method for normal distributions. All continuous variables were expressed as mean AE standard deviation, categorical variables were expressed as number (percentage). Spearman's correlation was used to determine in bivariate correlation the relationship and the strength of association between the variables. A probability value of P < 0.05 was considered to be statistically significant.
Results
The clinical characteristics of ADPKD patients are shown in Table 1 . The mean follow up was 52.80 AE 17.95 months. As anticipated, renal function has been gradually reduced in all patients. The slope of eGFR varies from −0.06 to −0.56 mL/mi/1.73 m 2 /month. The assessment of renal diameters in coronal, axial and sagittal allowed the calculation of the height-adjusted TKV (htTKV) ( Table 1) . MRI showed by colorimetric maps obtained both in early and late phase of the parenchymal fibrosis share, defined as 'fibrotic volume' (Fig. 1) and proportion of perfused parenchyma, defined as 'perfusion' volume ( Fig. 2) between the total perfusion volume and TKV, expressed as a percentage (TPV/TKV%) varied from 22 to 107% at T0 and from 12 to 91% at follow up (T1). The analysis of correlations between the TKV and eGFR at follow up (T1), showed a statistically significant negative correlation between the two parameters (r = −0.59, P = 0.02), while the same parameters evaluated at T0 showed no correlation (Fig. 3) . We found a trend of correlation between the TPV and eGFR at T1 (r = −12.48, P = 0.06). Moreover, we also found a negative correlation between eGFR and TFV (r = −0.61, P = 0.04), and eGFR with TPV/TKV % (r = −0.59, P = 0.02) at T1 (Fig. 4) . No significant correlations were found between TKV (r = 0.37, P = 0.16) and TPV/TKV % (r = −0.16, P = 0.56) with ADPKD, autosomal dominant polycystic kidney disease; htTKV, height-adjusted total kidney volume; PAC, plasma aldosterone concentration; TFV, total fibrotic volume; TKV, total kidney volume; TPV/TKV %, ratio between the total kidney volume and total perfusion volume expressed as a percentage.
progressive reduction of eGFR. Moreover, in this study PAC was correlated positively with the TFV (r = 0.50, P = 0.05). Subdividing patients according to age (21-34 and 35-51 years), aldosterone showed a significant correlation with the higher age class (r = 0.88, P < 0.003), and not in lower age (r = −0.03, P = 0.93). Our study also showed a positive correlation between the TFV with insulin values (r = 0:49, P < 0.05), ABI (r = 0.51, P < 0.05) and LVMI (r = 0.63, P < 0.01), but no significant correlation with IMT. PRA was in the normal range in all patients (data not shown).
Discussion
In the present study, we investigated a novel MRI protocol, using advanced imaging with 3Tesla high field magnet that through colorimetric maps in the early and late phase, with 3D reconstruction, identifies areas of parenchyma perfused called 'perfusion volume', and areas of renal fibrosis defined 'fibrotic volume'. TFV is a noncystic area of the polycystic kidney, likely characterised by peritubular interstitial fibrosis, tubular dilation, atrophy and vascular sclerosis. Total perfusion volume represents the non-cystic fraction of the polycystic kidney with a normal perfusion and tissue architecture. It is known that eGFR is a late marker of kidney damage in ADPKD, while the presence of fibrosis was documented in an early phase of disease, with preserved renal function and TKV slightly increased. The sequential evaluation of TKV and the cystic volume has been adopted in recent years in several clinical trials as a measure of outcome, but these showed no linear correlation with worsening renal function, if not in the late stages of the disease. In fact, the Consortium for Radiologic Imaging in Polycystic Kidney Disease cohort (CRISP) study, showed that in ADPKD patients magnetic resonancebased htTKV over 600 mL/m predicts the development of CKD Stage 3 within 8 years, and that TKV and cyst volume increase exponentially with age, but causal relationship between kidney or cyst volume increases and the progression to ESRD has not been completely demonstrated. In our study, TKV was negatively correlated with eGFR at T1, according with the CRISP study, 8 while the same parameters evaluated at T0 did not show any correlation, confirming that TKV and eGFR could not be correlated in the early stages of disease. Moreover, we showed a negative correlation between eGFR and TFV, and a positive correlation between eGFR and TPV/TKV % at T1, suggesting these as possible new markers that could be used to assess disease progression and efficacy to therapy. In fact, TPV showed a negative correlation, albeit without statistical significance, with eGFR at T1; perhaps this may also be due to the low number of the sample examined. Caroli et al. 3 have characterised extracystic tissue on contrast-enhanced computed tomography (CT), subdividing extracystic tissue into two separate components, fully enhanced and hypo-enhanced parenchyma tissue, called 'intermediate', showing that intermediate tissue significantly correlated with eGFR. Moreover in our study we showed that PAC was correlated positively with the TFV, and subdividing patients into age groups (21-34 and 35-51 years), PAC showed a Figure 3 Correlation between the total kidney volume (TKV) and estimated glomerular filtration rate (eGFR), at T0 (r = −0.31, P = 0.24) and at T1 (r = −0.59, P = 0.02) in autosomal dominant polycystic kidney disease patients. significant correlation with the higher age class, results however not correlated in patients with a lower age. The results obtained could confirm an involvement of the aldosterone in the development of renal fibrosis, especially in advanced stages, the outcome of a mechanism that starts already in the initial stage of the disease, and that gradually leads to irreversible loss of renal parenchyma. On the contrary, the PRA was normal in all patients. Valvo et al. 11 have suggested that the suppression of the renin-angiotensin-aldosterone system (RAAS) and low renin values in ADPKD patients could be due to an increased plasma volume. The production of aldosterone has been demonstrated also in extra adrenal tissue and appears to be only partially influenced by the plasma levels of angiotensin II. 21 It would be connected to the production of extracellular matrix and could, therefore, have a pathophysiological role in the genesis and progression of chronic kidney damage. In addition, normal PRA, does not exclude the presence of a strongly activated intrarenal RAAS, demonstrated in ADPKD patients, 22 with a local overproduction of angiotensin II and aldosterone, and consequent haemodynamic and chronic inflammatory tissue action. 7, 23 The hyperproduction of aldosterone determines arteriolar vasoconstriction, production of cytokines and adhesion molecules with consequent recall of inflammation cells, chemotaxis, activation of macrophages and growth of fibroblasts.
5 It is able, moreover, to stimulate coagulation, through the increases of plasminogen activator inhibitor Type I, the activation of platelets and the increase of their aggregation at the level of bleeding sites. Increased levels of aldosterone and angiotensin II could lead to systemic fibrosis, mitogenesis and stimulate the formation of cysts. 6 Many studies support the evidence of the aldosterone role in determining cardiovascular damage, regardless of angiotensin II and blood pressure. 5, 6, 12 Indeed the hormone could have a fibrotic effect on vascular smooth muscle cells, endothelial cells, cardiomyocytes and renal tissue. 24 Our results showed that TFV, was correlated positively also with insulin values, ABI index and LVMI. Currently, little is known about the link between the function of polycystins and insulin value, although recently Mao et al. 25 have shown that polycystins can regulate the secretion of insulin, expressed also in the beta cells of pancreatic islets. ABI is a simple, non-expensive and non-invasive marker of atherosclerosis. It has a high specificity to predict future cardiovascular outcomes. Price et al.
14 showed that the combination of IMT and ABI could have an additive effect for predicting CVD, also if in our study only ABI and not IMT results correlated with TFV. However, Tokiwa et al. 26 showed that in ADPKD patients with preserved renal function, ABI found no significant relationship with disease progression, while in our study ABI was significantly correlated with TFV. Currently, we have the need of novel biomarkers of functional loss and indexes of disease progression, especially to monitor the effectiveness of therapy. The relationship between eGFR and TKV is stronger during the later stages of disease and total cyst and kidney volume have been often utilised as outcome measures in clinical trials. However, Caroli et al. 3 showed that intermediate volume, as determined by CT, comparing with gold standard (three ADPKD patients underwent bilateral nephrectomy), mainly constituted by tubulointerstitial fibrosis, would be considered a better candidate marker for monitoring disease progression and, as outcome measures in ADPKD patients. Renal biopsy could represent the gold standard procedure but it could be negative and harmful, with the possibility to aggravate renal function, especially considering the high rates of complications following kidney biopsy. Already in 1968 Risdon et al. 27 showed that renal fibrosis is the best histological correlate of the progression of renal damage and long-term prognosis. The Figure 4 Correlation between the estimated glomerular filtration rate (eGFR) and total fibrotic volume (TFV) (r = −0.61, P = 004), and between eGFR and (ratio between the total kidney volume and total perfusion volume expressed as a percentage (TPV/TKV %)) (r = −0.59, P = 0.02) at T1 in autosomal dominant polycystic kidney disease patients.
Markers of progression in ADPKD
Internal Medicine Journal 48 (2018) 1505-1513decline in renal function in ADPKD patients remains concealed for years, as a consequence of increased GFR by surviving nephrons. The compression of expanding cysts on parenchymal tissue and the stretching of renal microvessels cause hypoperfusion and disruption of the normal tissue architecture leading to progressive renal functional loss. Tubulointerstitial damage is now recognised as an essential element in the decline of renal function. Recent findings that intermediate volume, as determined by CT, 3 is mainly constituted by interstitial fibrosis, confirm that this imaging parameter could be considered a strong candidate marker for monitoring progression of renal disease, outcomes and therapy efficacy in ADPKD patients. A 3 Tesla-Diffusion Tensor Imaging without contrast agent is already being used in ADPKD patients by Lupica et al., 28 with promising results on the evaluation of the fractional anisotropy and apparent diffusion coefficient and a good correlation with kidney function tests, but this method without contrast agent, is certainly safer with low eGFR (<30 mL/min), but is not able to assess renal fibrous components. Therefore, quantification and monitoring of fibrotic tissue and its evaluation relative to the preserved parenchyma could allow us to stratify ADPKD patients, monitor disease progression and evaluate the effects of early treatment strategies when renal function is still preserved and patients are considered not at high risk for normal eGFR.
Renal biopsy could represent the gold standard procedure but it could be negative and harmful, with the possibility to aggravate renal function, especially considering the high rates of complications following kidney biopsy (rupture of cysts, infection and even greater difficulties at the time of transplantation).
Limitations of the study
This study was conducted in a small cohort of ADPKD patients, therefore, it should be considered as hypothesis generating data, which need to be confirmed by further clinical studies with a larger number of patients. Moreover, the technique used to quantify the fibrotic and perfusion volume is 'time consuming', and considered limited to specialised centres with advanced imaging techniques. Therefore, a large clinical trial is necessary to confirm the results of our findings and that further longterm data on larger populations are needed to recommend the procedure in clinical practice.
Conclusion
Our results showed a possible method of advanced imaging, capable of identifying and quantifying the fibrotic and perfusion renal volume, already at an early stage of the disease, also with preserved renal function and a possible correlation with the eGFR. Indeed novel MRI protocol of advanced imaging with 3Tesla high field magnet could accurately reproduce these changes, even when renal function is still preserved. If our hypothesis is confirmed by larger clinical studies, it would be advisable to carry out a study with MRI 3Tesla high field magnet, in the follow up of ADPKD patients, to evaluate the progression of the disease and the effectiveness of new therapeutic strategies, despite the high costs.
